Bharat Biotech’s Covaxin 3rd phase clinical trials show 77.8% overall efficacy rate; vaccine 65.2% effective against Delta variant

Bharat Biotech’s Covaxin 3rd phase clinical trials show 77.8% overall efficacy rate; vaccine 65.2% effective against Delta variant

In a significant development, indigenously developed Bharat Biotech’s Coronavirus vaccine Covaxin has been found to be 77.8 percent effective against symptomatic Coronavirus infections, the result of the third phase of clinical trials of the vaccine showed. While the efficacy rate of the vaccine remained 77.8 percent against symptomatic Covid-19 cases, the trial results found that … Read more

Covaxin phase 3 trial results out, Bharat Biotech says its Covid vaccine has 81% efficacy rate

Covaxin phase 3 trial results out, Bharat Biotech says its Covid vaccine has 81% efficacy rate

The DGCI had said that the decision to grant emergency approval to the vaccine maker was given on the basis of earlier phases of clinical trials. Bharat Biotech, the Hyderabad-based pharma major, has released the efficacy data of its Coronavirus vaccine ‘Covaxin’ on Wednesday. reported. According to news agency ANI, the company said that its … Read more

Covaxin update: Here’s how Bharat Biotech secured nod for India’s first indigenous Covid-19 vaccine

Covaxin update: Here’s how Bharat Biotech secured nod for India’s first indigenous Covid-19 vaccine

Covaxin news, update: On January 3, the Ministry of Health and Family Welfare announced that Emergency Use Authorization (EUA) has been granted to Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin. With approvals of two Covid-19 vaccines—Covaxin (Bharat Biotech) and Covishield (Serum Institute-Oxford), India is all set to begin one of the world’s biggest … Read more